BridgeMD
New treatment option for Sarcopenia in Elderly
Official title Effect of Micronized Creatine Monohydrate on Muscle Mass, Strength and Performance in Older Adults Submitted to Total Knee Arthroplasty
ClinicalTrials.gov ID: NCT06925880
What this study is testing
- What it's testing
- Double-blind randomized placebo-controlled clinical trial with two parallel arms. The main objective is to evaluate the efficacy and safety of creatine supplementation in older adults who have been operated on for total knee arthroplasty and undergoing a usual rehabilitation program.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 and older
You may be able to join if
- Persons 65 years of age or older who have been operated on for the first time for total knee arthroplasty,
- who are undergoing an outpatient rehabilitation program according to standard clinical practice,
- who sign the informed consent form.
You likely can't join if
- Chronic renal disease at stage G3b or higher or glomerular filtration rate \<30 ml/min/1.73m2.
- Hepatic insufficiency, cirrhosis.
- Neuromuscular and neurodegenerative diseases (amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, Parkinson's...
- Severe or very severe chronic obstructive pulmonary disease (COPD) (GOLD III-IV).
- Moderate or severe chronic heart failure (NYHA 3-4).
- Central sensitivity syndrome (fibromyalgia and chronic fatigue syndrome).
See the full eligibility criteria
- Persons 65 years of age or older who have been operated on for the first time for total knee arthroplasty,
- who are undergoing an outpatient rehabilitation program according to standard clinical practice,
- who sign the informed consent form.
- Chronic renal disease at stage G3b or higher or glomerular filtration rate \<30 ml/min/1.73m2.
- Hepatic insufficiency, cirrhosis.
- Neuromuscular and neurodegenerative diseases (amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, Parkinson's disease, etc.).
- Severe or very severe chronic obstructive pulmonary disease (COPD) (GOLD III-IV).
- Moderate or severe chronic heart failure (NYHA 3-4).
- Central sensitivity syndrome (fibromyalgia and chronic fatigue syndrome).
- Moderate or severe cognitive impairment (GDS≥4).
- Moderate-severe dependence for basic activities of daily living (preintervention Barthel index \<60 points).
- Hemiparesis, amputation or malformation of any limb.
- Consumption of creatine monohydrate supplements in the last 6 months.
The study team makes the final eligibility decision.
Where it's taking place
- Mataró, Barcelona, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mataró, Barcelona, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.